Oxybutynin + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Overactive Detrusor
Conditions
Overactive Detrusor, Neurogenic Bladder
Trial Timeline
May 17, 2011 → Oct 24, 2023
NCT ID
NCT01192568About Oxybutynin + Placebo
Oxybutynin + Placebo is a approved stage product being developed by AbbVie for Overactive Detrusor. The current trial status is completed. This product is registered under clinical trial identifier NCT01192568. Target conditions include Overactive Detrusor, Neurogenic Bladder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01192568 | Approved | Completed |
Competing Products
20 competing products in Overactive Detrusor